What it does
Thermo Fisher states that its mission is to enable customers to make the world healthier, cleaner and safer. It supplies products and services for scientific research, drug and vaccine discovery and production, disease diagnosis, laboratory work, clinical development and commercial drug manufacturing. The company reports four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. Its offerings include reagents, instruments, consumables, software, diagnostic tests, laboratory products, and pharmaceutical and clinical-research services.
Source: Thermo Fisher Scientific Inc. Form 10-K for fiscal 2025, Item 1 — sec.gov
How it makes money
The company states that it sells products and services through its four reported segments; the segment table below provides the related revenue detail. Life Sciences Solutions supplies products for biological and medical research, drug and vaccine work, and disease diagnosis. Analytical Instruments sells instruments and related consumables, software and services. Specialty Diagnostics supplies diagnostic test kits, reagents, culture media, instruments and related products. Laboratory Products and Biopharma Services combines laboratory products and channels with outsourced drug-development, clinical-research, clinical-trials and commercial-manufacturing services. The filing says sales occur through direct sales personnel, customer-service professionals, e-commerce and third-party distributors.
Source: Thermo Fisher Scientific Inc. Form 10-K for fiscal 2025, Item 1 — sec.gov
Customers and geography
Thermo Fisher states that it serves pharmaceutical and biotech companies, hospitals, clinical diagnostic laboratories, universities, research institutions and government agencies. It also serves environmental, industrial, research-and-development, quality-control and process-control settings. The filing describes a global team and identifies customers across pharmaceutical, biotechnology, academic, government, research, industrial and clinical-laboratory markets. The supplied filing excerpt does not provide a geographic revenue breakdown. For its workforce, the company reports colleagues in the Americas, Asia-Pacific, and Europe, the Middle East and Africa.
Source: Thermo Fisher Scientific Inc. Form 10-K for fiscal 2025, Item 1 — sec.gov
Competition
The company states that it encounters aggressive and able competition in virtually all markets it serves. The filing lists its competitors as a broad range of manufacturers, third-party distributors and service providers; it does not name individual competitor companies. It says competitive conditions in many markets involve changing technology and customer demands requiring continued research and development. The company identifies technical performance and technology advances, product and service differentiation, availability, reliability, capabilities, customer reputation, service and support, research programs and relative prices as factors on which its success primarily depends.
Source: Thermo Fisher Scientific Inc. Form 10-K for fiscal 2025, Item 1 — sec.gov
Key risks
The filing gives prominence to the following risks:
- Markets into which the company sells products and services may decline, not grow as anticipated or experience cyclicality.
- The company must develop new products, adapt to rapid and significant technological change, respond to competitors’ new offerings and maintain quality.
- Reliance on sole or limited sources for certain materials or components could cause production interruptions, delays and inefficiencies.
- The company and its third-party providers experience cyber-attacks and attempts to gain unauthorized access to products, services, systems and data.
- New governmental regulations or changes in existing regulations may reduce demand or increase expenses.
- Fluctuations in the effective tax rate may adversely affect results of operations and cash flows.
Source: Thermo Fisher Scientific Inc. Form 10-K for fiscal 2025, Item 1A — sec.gov
People and operations
As of December 31, 2025, the company employed approximately 125,000 colleagues globally. The filing gives an approximate regional distribution of 59,000 in the Americas, 22,000 in Asia-Pacific, and 44,000 in Europe, the Middle East and Africa. It also states that it has approximately 14,000 sales personnel, including technical specialists. The company markets and sells through direct sales, customer-service professionals, e-commerce and third-party distributors. Seasonality is stated: fourth-quarter revenue has historically been stronger because of capital-spending patterns among industrial, pharmaceutical and government customers, while sales of allergy, flu and related diagnostic products vary by quarter and year.
Source: Thermo Fisher Scientific Inc. Form 10-K for fiscal 2025, Item 1 — sec.gov